Capricor Therapeutics (CAPR) Current Assets (2010 - 2026)

Capricor Therapeutics' Current Assets history runs 17 years deep, the most recent figure standing at $283.1 million for Q1 2026.

• On a quarterly basis, Current Assets rose 93.56% year-over-year to $283.1 million in Q1 2026; TTM through Mar 2026 was $283.1 million, a 93.56% increase from a year earlier, with the FY2025 full-year figure at $322.9 million, up 97.66% from the prior year.
• Current Assets eased to $283.1 million in Q1 2026 per CAPR's latest filing, from $322.9 million in the prior quarter.
• Across five years, Current Assets topped out at $322.9 million in Q4 2025 and bottomed at $29.5 million in Q3 2023.
• The 5-year median for Current Assets is $52.6 million (2022), against an average of $98.1 million.
• Across the five-year window, Current Assets plunged 37.84% in 2023 and jumped 304.73% in 2025, its largest moves.
• Year by year, Current Assets stood at $42.9 million in 2022, then advanced by 18.58% to $50.9 million in 2023, then surged by 221.27% to $163.4 million in 2024, then jumped by 97.66% to $322.9 million in 2025, then decreased by 12.34% to $283.1 million in 2026.
• Per Business Quant, the three latest CAPR Current Assets figures stand at $283.1 million (Q1 2026), $322.9 million (Q4 2025), and $101.0 million (Q3 2025).